Biophytis showcased the OBA program in obesity at the 17th SCWD international congress

Biophytis presented its OBA program with BIO101 at the 17th SCWD congress, highlighting its potential to prevent GLP-1RA-induced muscle loss in obesity. Results from the Quinolia study showed reduced fat mass and maintained muscle strength in 20-hydroxyecdysone-treated patients. A phase 2 OBA study targeting obese patients with GLP-1 RAs is planned for 2025.


Related News

Biophytis showcased the OBA program in obesity at the 17th SCWD international congress

Biophytis presented its OBA program with BIO101 at the 17th SCWD congress, highlighting its potential to prevent GLP-1RA-induced muscle loss in obesity. Results from the Quinolia study showed reduced fat mass and maintained muscle strength in 20-hydroxyecdysone-treated patients. A phase 2 OBA study targeting obese patients with GLP-1 RAs is planned for 2025.

© Copyright 2024. All Rights Reserved by MedPath